{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:17:58Z","timestamp":1768414678512,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/leu.2015.226","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T06:40:40Z","timestamp":1439880040000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial"],"prefix":"10.1038","volume":"30","author":[{"given":"J M","family":"Middeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Stuhler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"R\u00f6sler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Bitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Knoth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-5564","authenticated-orcid":false,"given":"N","family":"Alakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Schaich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Morgner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"von Bonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Study Alliance Leukemia (SAL)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,18]]},"reference":[{"key":"BFleu2015226_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453\u2013474.","journal-title":"Blood"},{"key":"BFleu2015226_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.beha.2013.10.005","volume":"26","author":"F Ravandi","year":"2013","unstructured":"Ravandi F . Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol 2013; 26: 253\u2013259.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu2015226_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0268-960X(03)00036-5","volume":"18","author":"MR Litzow","year":"2004","unstructured":"Litzow MR . The therapy of relapsed acute leukaemia in adults. Blood Rev 2004; 18: 39\u201363.","journal-title":"Blood Rev"},{"key":"BFleu2015226_CR4","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Cortes J, Faderl S, O\u2019Brien S, Garcia-Manero G, Verstovsek S et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010; 116: 5818\u20135823, quiz 6153.","journal-title":"Blood"},{"key":"BFleu2015226_CR5","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","volume":"109","author":"JJ Cornelissen","year":"2007","unstructured":"Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG et al. Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658\u20133666.","journal-title":"Blood"},{"key":"BFleu2015226_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J, Fr\u00f6hling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909\u20131918.","journal-title":"N Engl J Med"},{"key":"BFleu2015226_CR7","doi-asserted-by":"crossref","unstructured":"Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol 2015; e-pub ahead of print 30 July 2015; doi:10.1016\/S1470-2045(15)00201-6.","DOI":"10.1016\/S1470-2045(15)00201-6"},{"key":"BFleu2015226_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MOH.0b013e32834ff4e1","volume":"19","author":"Y Ofran","year":"2012","unstructured":"Ofran Y, Rowe JM . Treatment for relapsed acute myeloid leukemia: what is new? Curr Opin Hematol 2012; 19: 89\u201394.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2015226_CR9","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","volume":"121","author":"SJ Forman","year":"2013","unstructured":"Forman SJ, Rowe JM . The myth of the second remission of acute leukemia in the adult. Blood 2013; 121: 1077\u20131082.","journal-title":"Blood"},{"key":"BFleu2015226_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood-2013-12-541508","volume":"123","author":"RP Gale","year":"2014","unstructured":"Gale RP, Lazarus HM . Correcting 2 more myths regarding transplants for AML in second remission. Blood 2014; 123: 794.","journal-title":"Blood"},{"key":"BFleu2015226_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","volume":"105","author":"S Faderl","year":"2005","unstructured":"Faderl S, Gandhi V, O\u2019Brien S, Bonate P, Cortes J, Estey E et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940\u2013947.","journal-title":"Blood"},{"key":"BFleu2015226_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","volume":"30","author":"S Faderl","year":"2012","unstructured":"Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial951. J Clin Oncol 2012; 30: 2492\u20132499.","journal-title":"J Clin Oncol"},{"key":"BFleu2015226_CR13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","volume":"122","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013; 122: 1384\u20131394.","journal-title":"Blood"},{"key":"BFleu2015226_CR14","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","volume":"112","author":"S Faderl","year":"2008","unstructured":"Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638\u20131645.","journal-title":"Blood"},{"key":"BFleu2015226_CR15","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2009.26.4242","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389\u20132395.","journal-title":"J Clin Oncol"},{"key":"BFleu2015226_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0609.2012.01822.x","volume":"89","author":"P Chevallier","year":"2012","unstructured":"Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B et al. Clofarabine-containing conditioning regimen for allo-SCT in AML\/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012; 89: 214\u2013219.","journal-title":"Eur J Haematol"},{"key":"BFleu2015226_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbmt.2011.07.017","volume":"18","author":"MH Kirschbaum","year":"2012","unstructured":"Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012; 18: 432\u2013440.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2015226_CR18","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1182\/blood-2011-06-358010","volume":"118","author":"J Magenau","year":"2011","unstructured":"Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 2011; 118: 4258\u20134264.","journal-title":"Blood"},{"key":"BFleu2015226_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bbmt.2011.10.041","volume":"18","author":"K Van Besien","year":"2012","unstructured":"Van Besien K, Stock W, Rich E, Odenike O, Godley LA, O\u2019Donnell PH et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 913\u2013921.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2015226_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1\u201310.","journal-title":"Control Clin Trials"},{"key":"BFleu2015226_CR21","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/leu.2014.335","volume":"29","author":"J Schetelig","year":"2015","unstructured":"Schetelig J, Schaich M, Schafer-Eckart K, Hanel M, Aulitzky WE, Einsele H et al. Hematopoietic cell transplantation in patients with intermediate and high-risk AML - results from the randomized study alliance leukemia (SAL) AML 2003 trial. Leukemia 2015; 29: 1060\u20131068.","journal-title":"Leukemia"},{"key":"BFleu2015226_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2015226_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3324\/haematol.2012.063438","volume":"98","author":"PS Becker","year":"2013","unstructured":"Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J et al. Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica 2013; 98: 114\u2013118.","journal-title":"Haematologica"},{"key":"BFleu2015226_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","volume":"88","author":"S Buchholz","year":"2012","unstructured":"Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A et al. Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012; 88: 52\u201360.","journal-title":"Eur J Haematol"},{"key":"BFleu2015226_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2141.2011.08831.x","volume":"155","author":"PS Becker","year":"2011","unstructured":"Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011; 155: 182\u2013189.","journal-title":"Br J Haematol"},{"key":"BFleu2015226_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092\u20131099.","journal-title":"Blood"},{"key":"BFleu2015226_CR27","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675\u20135687.","journal-title":"J Clin Oncol"},{"key":"BFleu2015226_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/bmt.2011.15","volume":"47","author":"C Schmid","year":"2012","unstructured":"Schmid C, Schleuning M, Tischer J, Holler E, Haude K-H, Braess J et al. Early allo-SCT for AML with a complex aberrant karyotype\u2014results from a prospective pilot study. Bone Marrow Transplant 2012; 47: 46\u201353.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2015226_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.leu.2404143","volume":"20","author":"U Platzbecker","year":"2006","unstructured":"Platzbecker U, Thiede C, F\u00fcssel M, Geissler G, Illmer T, Mohr B et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20: 707\u2013714.","journal-title":"Leukemia"},{"key":"BFleu2015226_CR30","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/leu.2013.142","volume":"27","author":"F Stolzel","year":"2013","unstructured":"Stolzel F, Platzbecker U, Mohr B, Rollig C, Middeke JM, Thiede C et al. Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. Leukemia 2013; 27: 2068\u20132072.","journal-title":"Leukemia"},{"key":"BFleu2015226_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","volume":"35","author":"SL Price","year":"2011","unstructured":"Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 2011; 35: 301\u2013304.","journal-title":"Leuk Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015226","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:09:01Z","timestamp":1648742941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFleu2015226"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.226","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,18]]},"assertion":[{"value":"2 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consultant or advisory role: Johannes Schetelig and Jan Moritz Middeke: Sanofi. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}